Katja Klausz

Kiel, SH, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 42 publications

Combination of Fc-Protein Engineering Strategies: Design and Evaluation of Antibody Effector Functions.

Combination of Fc-Protein Engineering Strategies: Design and Evaluation of Antibody Effector Functions.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: May 13, 2026

CD19×CD3 bispecific T cell engager treatment induces remission in experimental pemphigoid disease.

CD19×CD3 bispecific T cell engager treatment induces remission in experimental pemphigoid disease.

Journal: Molecular therapy. Advances

Published: October 13, 2025

Myeloid cell-mediated killing of B-ALL by CD38 and CD20 IgA antibody variants is enhanced by CD47/SIRPα interference.

Myeloid cell-mediated killing of B-ALL by CD38 and CD20 IgA antibody variants is enhanced by CD47/SIRPα interference.

Journal: Blood neoplasia

Published: September 24, 2025

Complementary efficacy of CD127-directed immunotherapy with lusvertikimab and ABL-targeting tyrosine kinase inhibitors in preclinical ABL-class-fusion-positive B-ALL.

Complementary efficacy of CD127-directed immunotherapy with lusvertikimab and ABL-targeting tyrosine kinase inhibitors in preclinical ABL-class-fusion-positive B-ALL.

Journal: HemaSphere

Published: September 09, 2025

Memory-like Natural Killer Cell and CD19 Antibody-Based Immunotherapy in Combination with Tyrosine Kinase Inhibition Has Antitumor Effects against Ph(-like) Acute Lymphoblastic Leukemia.

Memory-like Natural Killer Cell and CD19 Antibody-Based Immunotherapy in Combination with Tyrosine Kinase Inhibition Has Antitumor Effects against Ph(-like) Acute Lymphoblastic Leukemia.

Journal: Cancer immunology research

Published: August 06, 2024

Combining Cellular Immunization and Phage Display Screening Results in Novel, FcγRI-Specific Antibodies.

Combining Cellular Immunization and Phage Display Screening Results in Novel, FcγRI-Specific Antibodies.

Journal: Viruses

Published: February 19, 2024

Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers.

Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers.

Journal: mAbs

Published: February 19, 2024

Generation and engineering of potent single domain antibody-based bispecific IL-18 mimetics resistant to IL-18BP decoy receptor inhibition.

Generation and engineering of potent single domain antibody-based bispecific IL-18 mimetics resistant to IL-18BP decoy receptor inhibition.

Journal: mAbs

Published: July 20, 2023

Identification of New Antibodies Targeting Tumor Cell Surface Antigens by Phage Display.

Identification of New Antibodies Targeting Tumor Cell Surface Antigens by Phage Display.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: July 05, 2023

Affinity Maturation of the Natural Ligand (B7-H6) for Natural Cytotoxicity Receptor NKp30 by Yeast Surface Display.

Affinity Maturation of the Natural Ligand (B7-H6) for Natural Cytotoxicity Receptor NKp30 by Yeast Surface Display.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: July 05, 2023

Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells.

Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells.

Journal: Frontiers in immunology

Published: May 23, 2023

NKp46-specific single domain antibodies enable facile engineering of various potent NK cell engager formats.

NKp46-specific single domain antibodies enable facile engineering of various potent NK cell engager formats.

Journal: Protein science : a publication of the Protein Society

Published: November 25, 2022

Showing 1-12 of 42

Last Updated: 09/26/2026